Lactam metalloprotease inhibitors

A compound of formula I:

• or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;
• A is —CONHOH;
• ring B is a 4 membered cyclic amide;
• R1 is —Z—Ua—Xa—Ya—Za;
• Z is phenylene substituted with 0-5 Rb;
• Ua is absent or is selected from:
• O, NRa, C(O)O, C(O)O, OC(O), C(O)NRa, NRaC(O), OC(O)O, OC(O)NRa, NRaC(O)O, NRaC(O)NRa, S(O)p, S(O)pNRa, NRaS(O)p, and NRaSO2NRa;
• Xa is absent or selected from C1-10 alkylene, C2-10 alkenylene, C2-10 alkynylene;
• Ya is absent or selected from O, NRa, S(O)p, and C(O);
• Za is selected from H, a C3-13 carbocyclic residue substituted with 0-5 Rc and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S and substituted with 0-5 Rc;
• R2 is amino or methyl;
• R, at each occurrence, is independently selected from H, CH3, CH2CH3, CH═CH2, CH═CH3, and CH2CH═CH2;
• R′, at each occurrence, is independently selected from H, CH3, CH2CH3, and CH(CH3)2;
• R3 is selected from Q, C1-10 alkylene-Q, C2-10 alkenylene-Q, C2-10 alkynylene-Q, (CRR′)r′O(CRR′)r—Q, (CRR′)r′NRa(CRR′)r—Q, (CRR′)rC(O)(CRR′)r—Q, (CRR′)rC(O)O(CRR′)r—Q, (CRR′)r′OC(O)(CRR′)r—Q, (CRR′)rC(O)NRa(CRR′)r—Q, (CRR′)r′NRaC(O)(CRR′)r—Q, (CRR′)r′OC(O)O(CRR′)r—Q, (CRR′)r′OC(O)NRa(CRR′)r—Q, (CRR′)r′NRaC(O)O(CRR′)r—Q, (CRR′)r′NRaC(O)NRa(CRR′)r—Q, (CRR′)r′S(O)p(CRR′)r—Q, (CRR′)r′SO2NRa(CRR′)r—Q, (CRR′)r′NRaSO2(CRR′)r—Q, (CRR′)r′NRaSO2NRa(CRR′)r—Q, (CRR′)r′NRaC(O)(CRR′)r″NHQ, (CRR′)r′NRaC(O)(CRR′)rNHC(O)ORa, and (CRR′)r′NRaC(O)(CRR′)rNHC(O)(CRR′)rNHC(O)ORa, provided that R3 is other than H;
• Q is selected from H, a C3-13carbocyclic residue substituted with 0-5 Rb and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S and substituted with 0-5 Rb;
• R4 is H;
• Ra, at each occurrence, is independently selected from H, C1-4 alkyl, phenyl and benzyl;
• Ra′, at each occurrence, is independently selected from H, C1-4 alkyl, phenyl and benzyl;
• Ra″, at each occurrence, is independently selected from H, C1-4 alkyl, benzyl, C3-7 carbocyclic residue, or a 5 to 6 membered heteroaromatic ring containing 1-4 heteroatoms. selected from the group consisting of N, O, and S;
• alternatively, Ra and Ra′ taken together with the nitrogen to which they are attached form a 5 or 6 membered ring containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
• Rb, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, I, ═O, CN, NO2, NRaRa′, C(O)Ra″, C(O)ORa, C(O)NRaRa′, S(O)2NRaRa′, S(O)pRa, CF3, and CF2CF3;
• Rc, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, I, ═O, CN, NO2, NRaRa′, C(O)Ra, C(O)ORa, C(O)NRaRa′, NRaC(O)NRaRa′, S(O)2NRaRa′, S(O)pRa, CF3, CF2CF3, —CH(═NOH), —C(═NOH)CH3, (CRR′)sO(CRR′)s′Rd, (CRR′)sS(O)p(CRR′)s′Rd, (CRR′)sNRa(CRR′)s′Rd, phenyl, and a 5-14 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;
• Rd, at each occurrence, is independently selected from phenyl substituted with 0-3 Rb, biphenyl substituted with 0-2 Rb, naphthyl substituted with 0-3 Rb and a 5-10 membered heteroaryl system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S and substituted with 0-3 Rb;
• p, at each occurrence, is selected from 0, 1, and 2;
• r, at each occurrence, is selected from 0, 1, 2, 3, 4, and 5;
• r′, at each occurrence, is selected from 0, 1, 2, 3, 4, and 5;
• r″, at each occurrence, is selected from 1, 2, and 3;
• s, at each occurrence, is selected from 0, 1, 2, and 3;
• and,
• s′, at each occurrence, is selected from 0, 1, 2, and 3.